Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University Weihui, Henan Province, P.R. China.
Department of Pharmaceutical Chemistry, Hamdard Institute of Pharmaceutical Sciences, Hamdard University, Islamabad, Pakistan.
PLoS One. 2024 May 24;19(5):e0302657. doi: 10.1371/journal.pone.0302657. eCollection 2024.
Ethnopharmacological relevance of Saussurea species for anti-cancer compounds instigated us to develop chemotherapeutic herbal tablets. This study was an ongoing part of our previous research based on the scientific evaluation of Saussurea heteromalla (S. heteromalla) for anti-cancer lead compounds. In the current study, S. heteromalla herbal tablets (500 /800 mg) were designed and evaluated for anti-cancer activity. Arctigenin was found as a bioactive lead molecule with anti-cancer potential for cervical cancer. The in vitro results on the HeLa cell line supported the ethnopharmacological relevance and traditional utilization of S. heteromalla and provided the scientific basis for the management of cervical cancer as proclaimed by traditional practitioners in China. LD50 of the crude extract was established trough oral acute toxicity profiling in mice, wherein the minimum lethal dose was noticed as higher than 1000 mg/kg body weight orally. Chromatographic fingerprint analysis ensured the identity and consistency of S. heteromalla in herbal tablets in terms of standardization of the herbal drug. About 99.15% of the drug (S. heteromalla crude extract) was recovered in herbal tablets (RSD: 0.45%). In vitro drug release profile was found to be more than 87% within 1 h, which was also correlated with different mathematical kinetic models of drug release (r2 = 0.992), indicating that drug release from matrix tablets into the blood is constant throughout the delivery. The dosage form was found stable after an accelerated stability parameters study which may be used for anti-cervical cancer therapy in the future, if it qualifies successful preclinical investigation parameters.
藏药雪莲用于抗癌化合物的民族药理学相关性启发我们开发了化疗草药片剂。本研究是我们之前基于对雪莲(Saussurea heteromalla)进行抗癌先导化合物的科学评估的研究的延续。在当前的研究中,设计并评估了雪莲草药片剂(500/800mg)的抗癌活性。发现牛蒡子苷元是一种具有抗癌潜力的生物活性先导分子,可用于宫颈癌。在 HeLa 细胞系上的体外结果支持了雪莲的民族药理学相关性和传统用途,并为中国传统从业者所宣称的宫颈癌管理提供了科学依据。通过对小鼠进行口服急性毒性分析确定了粗提取物的 LD50,其中最低致死剂量被认为高于 1000mg/kg 体重口服。色谱指纹分析确保了草药片剂中雪莲的身份和一致性,从而实现了草药药物的标准化。草药片剂中约 99.15%的药物(雪莲粗提取物)被回收(RSD:0.45%)。体外药物释放曲线在 1 小时内发现超过 87%,这也与药物释放的不同数学动力学模型相关(r2=0.992),表明基质片剂向血液中释放药物是恒定的。在加速稳定性参数研究后,发现该剂型稳定,如果它符合成功的临床前研究参数,将来可能用于宫颈癌治疗。